文献速递膀胱癌与上尿路尿路上皮癌

放射性相关肌层浸润性膀胱癌的临床特征

Clinical characterization of radiation-associated muscle-invasive bladder cancer.
PubMed 文献 · Urology · 2021-04-20

基于SEER数据库1988-2015年60,090例MIBC患者,比较1,093例放射性相关MIBC与58,997例原发性MIBC。RA-MIBC诊断时T4比例更高(21.0% vs 17.3%,P<.001),淋巴结阳性比例更低(10.3% vs 17.1%,P<.001)。RA-MIBC的5年膀胱癌特异性死亡率更高(56.1% vs 35.3%,AHR 1.24,P<.001),校正后仍显著。

要点

  • RA-MIBC诊断时T4和高级别比例更高,淋巴结阳性比例更低。
  • RA-MIBC的5年膀胱癌特异性死亡率显著高于原发性MIBC(56.1% vs 35.3%)。
  • 校正分期、分级和治疗后,RA-MIBC死亡风险仍更高(AHR 1.24)。

核心结论

  • RA-MIBC较原发性MIBC诊断时分期和分级更高,接受治愈性治疗更少,生存更差。
  • 校正分期、分级和治疗后,RA-MIBC仍与更高的膀胱癌特异性死亡风险独立相关。

研究设计与样本

  • 基于SEER数据库1988-2015年诊断的60,090例MIBC患者进行回顾性队列分析。
  • 按既往盆腔原发癌是否接受放疗,分为RA-MIBC组(1,093例)和原发性MIBC组(58,997例)。
  • 采用Fine-Gray竞争风险回归比较校正后的膀胱癌特异性死亡率。

主要发现

  • RA-MIBC诊断时T4比例为21.0%,原发性MIBC为17.3%(P<.001)。
  • RA-MIBC淋巴结阳性比例为10.3%,原发性MIBC为17.1%(P<.001)。
  • RA-MIBC的5年膀胱癌特异性死亡率为56.1%,原发性MIBC为35.3%(AHR 1.24,P<.001)。

临床怎么用

  • 对既往盆腔放疗史患者应警惕RA-MIBC可能,诊断时需注意更高分期和分级。
  • RA-MIBC患者接受治愈性治疗的比例可能更低,需个体化评估治疗策略。
  • RA-MIBC预后较原发性MIBC更差,随访和监测应更积极。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the presentation, patterns of care, and outcomes of radiation-associated muscle-invasive bladder cancer (RA-MIBC) compared to primary (non-radiation associated) MIBC. RA-MIBC has been suggested to represent a more aggressive disease variant and be more difficult to treat compared to primary (non-radiation associated) MIBC. METHODS: We identified 60,090 patients diagnosed with MIBC between 1988-2015 using the Surveillance, Epidemiology, and End Results database and stratified patients based on whether radiation had been administered to a prior pelvic primary cancer. We used Fine-Gray competing risks regression to compare adjusted bladder cancer-specific mortality (BCSM) for RA-MIBC compared to primary MIBC. RESULTS: There were 1,093 patients with RA-MIBC and 58,997 patients with primary MIBC. RA-MIBCs were more likely to be T4 at diagnosis (21.0% vs 17.3%, P < .001), and less likely to be node-positive (10.3% vs 17.1%, P < .001). The rate of 5-year BCSM was significantly higher for patients with RA-MIBC vs primary MIBC (56.1% vs 35.3%, AHR 1.24, P < .001), even after stratification by other tumor, treatment and patient-specific factors. CONCLUSION: RA-MIBCs tended to present with higher grade and T stage disease and were less likely to receive curative treatment. Even when accounting for stage, grade, and receipt of treatment, patients with RA-MIBC had worse survival compared to those with primary MIBC. These findings suggest that RA-MIBC present unique clinical challenges and may also represent a biologically more aggressive disease compared to primary MIBC. Future research is needed to better understand the biology of RA-MIBC and develop improved treatment approaches.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sha ST, Dee EC, Mossanen M, et al. Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology. 2021. PMID: 33857569. doi:10.1016/j.urology.2021.03.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。